At this time, New York Oncology Hematology does not have access to acquire and administer the new COVID prophylaxis shot Evusheld for immunocompromised patients. We await further guidance from NYS and will keep our patients updated.

Clinical Trials & Research

Sitravatinib + Nivo Adv/Met Urothelial

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

Disease Types: Bladder,&nbs

Available at: {clinical_trial_location backspace="7"}Sitravatinib + Nivo Adv/Met Urothelial, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}